Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

31 / 39

Higher ALK mutations and bypass
Yu – Lung Cancer 2019
59% ALK mutations
47% By-pass
49% ALK mutations
20% By-pass
MET, ERBB3/4, KRAS
PIK3CA, NF1/2 mut.
HGF, EGFR amplif.